We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

NMR-Based Method Measures Circulating Blood Citrate Levels

By LabMedica International staff writers
Posted on 31 Mar 2021
Print article
Image: The Vantera Clinical Analyzer based on nuclear magnetic resonance (Photo courtesy of Liposcience)
Image: The Vantera Clinical Analyzer based on nuclear magnetic resonance (Photo courtesy of Liposcience)
Recent studies show that citrate is involved in several biological processes such as inflammation, cancer, insulin secretion, acetylation of histones, neurological development and hydroxylglutaric aciduria, indicating that it has functions beyond energy regulation.

Citrate associations with glaucoma, non-alcoholic fatty liver disease (NAFLD), bone disease and mortality have been observed. Monitoring circulating citrate could potentially be a diagnostic tool. While at present, urinary citrate is commonly used as a risk factor in kidney stone formation, serum/plasma citrate is scarcely utilized for disease diagnosis or prognosis.

Laboratorians at the Laboratory Corporation of America Holdings (Labcorp, Morrisville, NC, USA) took blood samples from volunteers in Greiner tubes allowed to clot (30 minutes) in an upright position and centrifuged (3,000 rpm, 10-15 minutes) immediately after clotting. Samples collected into plain red-top tubes and BD Gel Barrier serum tube (Becton Dickinson and Company, Franklin Lakes, NJ, USA) were held upright (red-top tubes for 45 minutes; BD Gel Barrier tubes for 30 minutes) at room temperature to clot and were promptly centrifuged.

Sample preparation (i.e., 1:1 (v/v) dilution of serum or plasma with phosphate buffer) was performed automatically on the Vantera Clinical Analyzer (Liposcience, Raleigh, NC). One-dimensional 1H NMR spectra were collected on a 400 MHz spectrometers at 47 °C. WET was used to suppress the water signal. The total acquisition time for each spectrum was 48 seconds. The NMR instruments are calibrated using 15 mM trimethyl acetic acid as a calibrator and reference standard to verify instrument performance on a daily basis. A restricted region of the collected spectrum, where the four citrate resonances appear, was used for quantification. To determine if the assay has adequate sensitivity to measure clinically relevant concentrations of citrate, the assay was used to quantify citrate in 533 apparently healthy adults, and in the general population (n=133,567).

The team reported that the limit of quantification (LOQ) for the assay was determined to be 1.48 mg/dL. Linearity was demonstrated over a wide range of concentrations (1.40 to 4.46 mg/dL). Coefficients of variation (%CV) for intra- and inter-assay precision ranged from 5.8-9.3 and 5.2-9.6%, respectively. Substances tested did not elicit interference with assay results. Specimen type comparison revealed <1% bias between serum and plasma samples, except for heparin plasma (3% bias). Stability was demonstrated up to eight days at room temperature and longer at lower temperatures. In a cohort of apparently healthy adults, the reference interval was <1.48 to 2.97 mg/dL. Slightly higher values were observed in the general population.

The authors concluded that the newly developed NMR-based assay exhibits analytical characteristics that allow the accurate quantification of clinically relevant citrate concentrations. The assay provides a simple and fast means to analyze samples for clinical and other studies. The study was published on March 18, 2021 in the journal Practical Laboratory Medicine.

Related Links:
Laboratory Corporation of America Holdings
Becton Dickinson and Company
Liposcience


Gold Supplier
SARS-COV-2 IgM/IgG Rapid Qualitative Test
GLINE-2019-nCoV IgM/IgG Rapid Qualitative Test
New
Gold Supplier
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
New
Gold Supplier
COVID-19 Antigen Test
Rapid COVID-19 Antigen Test
New
SARS-CoV-2 Assay
Solana SARS-CoV-2 Assay

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.